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Abstract
Background: IL-4-driven alternative macrophage activation and proliferation are characteristic features of both
antihelminthic immune responses and wound healing in contrast to classical macrophage activation, which
primarily occurs during inflammatory responses. The signaling pathways defining the genome-wide microRNA
expression profile as well as the cellular functions controlled by microRNAs during alternative macrophage
activation are largely unknown. Hence, in the current work we examined the regulation and function of
IL-4-regulated microRNAs in human and mouse alternative macrophage activation.
Methods: We utilized microarray-based microRNA profiling to detect the dynamic expression changes during human
monocyte–macrophage differentiation and IL-4-mediated alternative macrophage activation. The expression changes
and upstream regulatory pathways of selected microRNAs were further investigated in human and mouse in vitro and
in vivo models of alternative macrophage activation by integrating small RNA-seq, ChIP-seq, ChIP-quantitative PCR, and
gene expression data. MicroRNA-controlled gene networks and corresponding functions were identified using a
combination of transcriptomic, bioinformatic, and functional approaches.
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Results: The IL-4-controlled microRNA expression pattern was identified in models of human and mouse alternative
macrophage activation. IL-4-dependent induction of miR-342-3p and repression of miR-99b along with miR-125a-5p
occurred in both human and murine macrophages in vitro. In addition, a similar expression pattern was observed in
peritoneal macrophages of Brugia malayi nematode-implanted mice in vivo. By using IL4Rα- and STAT6-deficient
macrophages, we were able to show that IL-4-dependent regulation of miR-342-3p, miR-99b, and miR-125a-5p is
mediated by the IL-4Rα–STAT6 signaling pathway. The combination of gene expression studies and chromatin
immunoprecipitation experiments demonstrated that both miR-342-3p and its host gene, EVL, are coregulated directly
by STAT6. Finally, we found that miR-342-3p is capable of controlling macrophage survival through targeting an
anti-apoptotic gene network including Bcl2l1.
Conclusions: Our findings identify a conserved IL-4/STAT6-regulated microRNA signature in alternatively activated
human and mouse macrophages. Moreover, our study indicates that miR-342-3p likely plays a pro-apoptotic role in
such cells, thereby providing a negative feedback arm to IL-4-dependent macrophage proliferation.
Background
Macrophages display substantial functional heterogeneity,
allowing them to participate in diverse aspects of the
immune response, including immediate defense against
pathogens, regulation of lymphocyte activation, and clear-
ance of cell debris and microbes through phagocytosis,
and to contribute to tissue regeneration [1, 2]. Macro-
phage polarization states and functional properties are
determined by the tissue microenvironment containing
cytokines, different pathogen-derived molecules, as well as
lipid mediators [3]. Two well-established end points of
macrophage polarization are classic (M1) and alternative
(M2) macrophage activation induced by the Th1-type
cytokine interferon gamma and bacterial lipopolysacchar-
ide (LPS) and the Th2-type cytokines interleukin (IL)-4
and IL-13, respectively [3, 4]. M1-type macrophage ac-
tivation is triggered either by the activation of the Janus
kinase (JAK)/signal transducer and activator of tran-
scription (STAT1) axis or the activator protein 1 (AP-1)
and nuclear factor kappa-light-chain-enhancer of acti-
vated B cells (NFkB) signaling pathways, resulting in
enhanced bactericidal capacity and pro-inflammatory
properties [3, 5]. In contrast, IL-4 activates the IL4Rα/
JAK/STAT6 and phosphoinositide 3-kinase (PI3K)
pathways, both of which contribute to alternative
macrophage activation [6]. M2-type macrophages pos-
sess a characteristic gene expression signature endow-
ing them with anti-inflammatory and immune
regulatory properties. The significance of alternative
macrophage activation has been described in a range of
physiological and pathological processes, including
hypersensitivity, anti-helminthic immune responses, fibro-
sis, sepsis, and tumor progression [4, 6–8]. The functional
properties associated with distinct macrophage activation
states require tight but plastic regulation of activation-
specific gene expression programs at the transcriptional
and post-transcriptional levels [9]. In the past decade it
has been shown that microRNAs (miRNAs) are important
components of post-transcriptional fine tuning of gene ex-
pression in mammals [10–12].
miRNAs are short, 18–25-nucleotide-long, single-
stranded, non-coding RNA molecules. They are tran-
scribed from different regions of the genome, including
intergenic and intronic/exonic regions of protein-coding
genes, by RNA polymerase II. Primary transcripts are
processed in two steps during miRNA biogenesis by the
RNase III enzymes Drosha and Dicer [13]. The mature
miRNAs are incorporated into the RNA-induced silen-
cing complex (RISC) [11] and generally bind the 3′ un-
translated region (3′ UTR) of target messenger RNAs
(mRNAs) and act as negative regulators of gene expres-
sion through inhibition of protein synthesis and/or in-
duction of target mRNA degradation [10, 11]. Several
miRNAs, such as miR-155, miR-21, and miR-146, are
induced in macrophages in response to LPS, suggesting
that they have a role in the regulation of macrophage ac-
tivation and M1-type polarization [14–18]. In addition, a
number of miRNAs have recently been linked to alterna-
tive macrophage activation. For instance, miR-125b-5p,
miR-199b, and miR-378-3p showed elevated expression
in nematode infection-elicited alternative macrophage
activation [19]. Among these miRNAs, miR-378-3p has
been shown to repress IL-4-driven macrophage prolifer-
ation through the modulation of the PI3K/AKT signaling
pathway [19]. Furthermore, miR-124, miR-324-5p, and
miR-511-3p have been shown to fine-tune macrophage
functions during allergic inflammation and tumor devel-
opment, conditions characterized by the predominance
of alternative macrophage activation [20–23]. Finally,
miR-193b has been found to be induced by IL-4 in hu-
man macrophages, although its function remains un-
known [24].
Despite the fact that IL-4-induced alternative macro-
phage activation-specific miRNAs have been identified in
human and mouse in in vitro as well as in vivo models
[19, 24], the regulatory mechanisms of miRNA expression
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and their role during alternative macrophage activation re-
main poorly understood. In this work we identified the
human alternative macrophage activation-specific micro-
RNome using miRNA microarray and quantitative PCR
(qPCR) techniques. We found IL-4-dependent induction
of miR-342-3p and miR-193b and repression of miR-99b
and miR-125a-5p. Intriguingly, IL-4-dependent regulation
of miR-342-3p, miR-99b, and miR-125a-5p is conserved
between human cells and mouse bone marrow-derived
macrophages. Furthermore, these miRNAs show the same
expression pattern in an in vivo mouse model of parasitic
infection. The IL-4-regulated expression of miR-342-3p,
miR-99b, and miR-125a-5p is dependent on IL-4Rα and
STAT6 expression as demonstrated by loss of function
genetic experiments. Additionally, miR-342-3p and its
host gene, Evl (Ena/Vasp-like), are co-regulated during IL-
4-induced alternative macrophage activation in mouse.
Chromatin immunopreciptiation (ChIP) confirmed that
STAT6 directly binds to the regulatory region of the EVL
gene in IL-4-stimulated human and mouse macrophages.
Functional analyses combined with miRNA manipulation
studies demonstrated that miR-342-3p decreases the
viability of macrophages by inducing apoptosis. In silico
target prediction and functional analyses identified the
anti-apoptotic direct target gene network of miR-342-3p,
which includes Bcl2l1. These findings suggest that en-
hanced miR-342-3p expression is a component of a nega-
tive feedback loop controlling excessive macrophage
proliferation during Th2-type inflammatory responses.
Methods
Cell isolation and culture
Isolation of human monocytes, mouse bone marrow cells,
and mouse peritoneal macrophages was done as described
earlier with minor modifications [19, 25, 26]. CD14+ hu-
man monocytes were isolated from platelet-free buffy
coats from healthy donors by Ficoll gradient centrifuga-
tion followed by immunomagnetic cell separation with
anti-CD14-conjugated microbeads (VarioMACS Separ-
ation System, Miltenyi Biotec.). Monocytes were cultured
in multiwell culture plates in RPMI 1640 (Sigma-Aldrich)
supplemented with 10 % fetal bovine serum (Invitrogen)
and penicillin/streptomycin (Sigma-Aldrich). For macro-
phage differentiation and alternative macrophage activa-
tion, freshly plated monocytes were treated with IL-4
(100 ng/ml; PreproTech). Cells were harvested 12 and
72 h after cytokine treatment. Bone marrow isolation and
bone marrow-derived macrophage (BMDM) differenti-
ation were performed as described before [26]. Bone mar-
row was flushed from the femur of wild-type (WT), IL-
4Rα, and STAT6 knockout (KO) male animals. Cells were
purified through a Ficoll-Paque gradient (Amersham Bio-
sciences, Arlington Heights, IL, USA) and cultured in
DMEM containing 20 % endotoxin-reduced fetal
bovine serum and 30 % L929 conditioned medium for
5 days. For alternative macrophage activation we
treated freshly isolated bone marrow cells with IL-4
(5 ng/ml; PreproTech). Culture medium was changed
for Macrophage SFM medium (Gibco) on the 5th day.
IL-4 (20 ng/ml) was further added to the culture of
macrophage colony stimulating factor (MCSF)- and IL-
4-pretreated macrophages for 24 h for the alternative
macrophage activation. Peritoneal exudate cells from
Brugia malayi-infected animals were seeded at 5 × 106
cells per well to six-well cell culture plates (NUNC) in
RPMI, 5 % fetal calf serum, 2 mML-glutamine, 0.25 U/
mL penicillin, and 100 mg/mL streptomycin. After 4 h of
incubation at 37 °C, 5 % CO2, non-adherent cells were
washed off and the adherent cells were lysed in 700 μL
Qiazol.
Animals and infection
Wild-type mice (WT; C57BL/6J or BALB/c), Stat6-
deficient (Stat6 KO) mice on C57BL/6 J, and IL-4
receptor-α-deficient (IL-4Rα KO) mice on a BALB/c
background were housed under minimal disease condi-
tions. Surgical implantation of adult B. malayi parasites
into WT (C57BL/6) mice was carried out as described
previously [19] and performed by the same group and at
the same facilities as in case of of the results presented
by Jenkins et al. [27].
Flow cytometry
Macrophages were resuspended in staining medium
(phenol-red free DMEM, 10 mM HEPES, 2 % fetal bo-
vine serum) and incubated with anti-mouse CD206
(AbD Serotec), anti-human CD206 (BD Biosciences),
or corresponding unspecific isotype control antibodies
for 20 minutes at 4 °C. Cells were washed and resus-
pended in staining medium for flow cytometry. Data
acquisition was performed using a FACSAria III instru-
ment (BD Biosciences) and data were analyzed with
FlowJo software.
Arginase activity
Arginase activity measurement was performed as previ-
ously described with minor modifications [28].
miRNA microarray and data analysis
Global miRNA expression data were obtained with
Affymetrix miRNA 1.0 arrays (Affymetrix). Total RNA
samples were labeled using an Affymetrix FlashTag Bio-
tin HSR RNA Labeling Kit according to the manufac-
turer’s protocol. Briefly, 500 ng of total RNA samples
were poly(A)-tailed using poly A polymerase enzyme
and ATP at 37 °C for 15 minutes, then biotinylated by
ligating biotin-labeled fragment to the 3′ end. Labeled
samples were hybridized on miRNA 1.0 arrays at 48 °C
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and 60 rpm for 16 h. After that, arrays were washed
and stained using the standard Affymetrix protocol
with an Affymetrix Hybridization, Wash, and Stain Kit
on a FS 450 fluidic station instrument. The arrays were
scanned using an Affymetrix GeneChip Scanner 3000
7G instrument.
The miRNA CEL files were processed with R, using
affy and mirna10cdf packages [29, 30]. Raw expression
values were processed with the robust multi-array
average (RMA) procedure (background adjustment, quan-
tile normalization, and summarization of log-expression
values for each miRNA for each array) [31]. Only probes
annotated as human miRNAs were kept. Lowly expressed
probes were removed if expression was lower than the
median in at least two samples. The interquartile range
was calculated across all samples for each probe to deter-
mine the most variable probe of those mapped to the
same miRNA; 563 probes were annotated, expressed, and
unique. Quality control was performed using principal
component analysis. Differential expression analysis was
performed using the limma package [32, 33] by fitting a
linear model for each probe then using an empirical Bayes
method to get moderated t-statistics. The Benjamini and
Hochberg method was used to calculate false discovery
rates (FDRs) [34].
Small RNA-Seq and data analysis
A cDNA library for small RNA-Seq was generated from
1 μg total RNA using an Illumina TruSeq Small RNA
Sample Preparation kit, according to manufacturer’s
protocol. Briefly, after ligation of 3′ and 5′ RNA adapters,
reverse transcription was performed to synthesize cDNA;
then the cDNA was amplified using a common primer
and primer-containing index sequence. The amplified
product/library was excised from gel (6 % Novex TBE
PAGE gel) and, after purification, the libraries were quan-
tified by Qubit fluorometer and checked on a BioAnalyzer
2100 using DNA1000 chip (Agilent Technologies). The
small RNA-Seq libraries were diluted to 10 nM and five
libraries were pooled together before sequencing. A
single-read 50-bp sequencing run was performed on an
Illumina HiScan SQ instrument (Illumina, San Diego,
CA, USA). Each library pool were sequenced in one
lane of a sequencing flow cell; 16–18 million reads per
sample was obtained. Sequencing results from small RNA
libraries were 3′ adapter trimmed and de-duplicated using
the reaper and tally command-line tools from Kraken
[35]. The processed small RNA-Seq reads were mapped to
all available Mus musculus mature miRNA sequences
(miRBase v21 [36]). Read mapping was performed using
Bowtie [37]. The mapping process for reads longer than
ten nucleotides allowed two mismatches. Quantification
of mapped reads with minimum and maximum lengths of
18 and 24 nucleotides overlapping mature miRNA regions
(miRBase v21) was performed using the R package Geno-
micRanges [38, 39]. The minimum overlap between
mapped reads and mature regions was 16. We filtered out
mature miRNAs with counts per million (cpm) lower than
or equal to 4 cpm across at least three libraries. Differen-
tial expression analysis was performed using the edgeR
package [40] fitting a negative binomial generalized linear
model for each mature miRNA and then the likelihood ra-
tio test was performed. The comparisons were: WT in the
presence of IL-4 versus WT control, WT in the presence
of IL-4 versus STAT6 KO in the presence of IL-4, STAT6
KO in the presence of IL-4 versus STAT6 KO control, and
WT control versus STAT6 KO control. The Benajmini
and Hochberg method was used to calculate FDRs [34].
Real-time qPCR
Total RNA was isolated from cells using Tri Reagent
(MRC) according to the manufacturer’s protocol. For
quantification of mRNAs, pri-miRNAs, and mature
miRNAs, reverse transcription was performed using a
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). Reverse transcription (RT) primers for mature
miRNAs were supplied by Applied Biosystems. Transcript
quantification was performed by quantitative real-time
RT-PCR using Taqman probes or SYBR Green assays
(selfmade assays) and Taqman Gene Expression Assays
(Applied Biosystems).
For semi-quantitative PCR-based quantification of miR-
125a_Ncrna00035 in unstimulated and IL-4-stimulated
macrophages, specific primers were designed with Primer3.
The PCR program used for semi-quantitative amplification
was: 95 °C for 10 minutes, followed by 25 cycles of 30 s at
95 °C, 60 s at 65 °C, and 30 s at 72 °C. PCR products were
separated by agarose gel electrophoresis and visualized by
GelRed staining. qPCR assays and primer sequences are
listed in Additional file 1.
GRO-seq and ChIP-seq data analysis
All samples were aligned to the mouse reference genome
(mm9) [41] and RNA-Seq data were analyzed using the
standard TopHat/Cufflinks pipeline [42]. For ChIP-seq
and GRO-seq (global run-on sequencing) data an inte-
grative analysis pipeline was applied [43]. Data were vi-
sualized in Integrated Genome Browser [44].
Chromatin immunopreciptiation
ChIP was performed as previously described with minor
modifications [45]. Briefly, cells were crosslinked with
DSG (Sigma) for 30 minutes and then with formalde-
hyde (Sigma) for 10 minutes. After fixation, chromatin
was sonicated with a Diagenode Bioruptor to generate
200–1000-bp fragments. Chromatin was immunopreci-
pitated with antibodies against pre-immune IgG (Milli-
pore, 12–370), H3K27ac (Abcam, ab4729) and STAT6
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(Santa Cruz, sc-981). Chromatin–antibody complexes
were precipitated with Protein A-coated paramagnetic
beads (Life technologies). After six washing steps, com-
plexes were eluted and reverse crosslinked. DNA frag-
ments were column purified (Qiagen, MinElute). The
amount of immunoprecipitated DNA was quantified
with a Qubit fluorometer (Invitrogen). DNA was ap-
plied for qPCR analysis. Primer sequences are listed in
Additional file 2.
Transient transfection
To determine the potential function of miR-342-3p,
RAW264.7 cells were transfected with 30 nM miR-342-
3p precursor (Applied Biosystems) or scrambled miRNA
negative control (Applied Biosystems) using Dharma-
FECT 3 (Thermo Scientific) in 12- and 96-well plates
(Sigma-Aldrich) and eight-well chamber slides (Thermo
Scientific).
mRNA microarray and computational target identification
The raw sample CEL files were processed within R using
the affy, org.Mm.eg.db and mogene10stv1cdf packages
[29, 46, 47] Similarly to the miRNA microarray process-
ing, raw expression values were processed with the
RMA procedure [31]. The interquartile range was calcu-
lated across all samples for each probe in an identical
way to the miRNA microarray methodology to remove
probes mapping to the same transcript. Quality control
was performed using principal component analysis. Dif-
ferential expression analysis was performed as men-
tioned in the “miRNA microarray and data analysis”
section, using the limma package [32] to fit a linear
model to each probe then using an empirical Bayes
method to determine moderate t-statistics. The compari-
son used was transfection with miR-342-3p versus miR-
negative control miRNA mimics in the mouse macro-
phage cell line RAW264.7. The Benjamini and Hochberg
method was used to calculate FDRs [31]. The compari-
son was used to verify direct effects due to miR-342-3p
regulation. Sylamer [48] was used to quantify the enrich-
ment or depletion of miRNA seed matches in the 3′
UTRs of genes. The genes with enriched 3'UTRs were
ordered according to the t-statistic (differential expres-
sion). Prediction of functional miRNA targets was per-
formed by TargetExpress (C Ovando-Vázquez, D Lepe-
Soltero, C Abreu-Goodger, submitted). TargetExpress is
a support vector machine combination based on Tar-
getScan [49] and microT-CDs [50] predictions and an
expression profile. In this case, the miR-negative control
expression profile was included in the TargetExpress
model.
The 3′ UTR sequences corresponding to selected
downregulated and computationally predicted anti-
apoptotic mmu-miR-342-3p target genes were obtained
using the TxDb.Mmusculus.UCSC.mm10.ensGene and
GenomicFeature packages [38, 51] Conservation scores
for these 3′ UTR sequences were obtained from the
UCSC GenomeBrowser using the rtracklayer package
[52], selecting the track cons60way to obtain the phast-
Cons60wayPlacental table.
Cell number analysis
Propidium iodide (PI)-based cell number analysis was
performed as previously described with minor modifica-
tions [53]. Briefly, macrophages attached to the bottom
of 96-well plates were permeabilized by Triton X-100,
stained by PI and measured in a Synergy HT microplate
reader (Bio-Tek Instruments, Winooski, VT, USA) at
530/25 nm excitation and 645/40 nm emission. Cell
numbers were determined using the cell number refer-
ence curve.
Cell viability analysis
Resazurin-based viability staining (Promega) was carried
out according to the manufacturer’s protocol. Neutral
red staining was performed as previously described with
minor modifications [54].
Cell cycle analysis
We plated 2 × 104 cells per well in Labtek 8-well cham-
bered coverslips and transfected them with appropriate
miRNAs. Cell fixation and PI staining were performed
48 h post-transfection as previously described [55] with
minor modifications. Raw264.7 cells were fixed on cham-
ber slides using −20 °C methanol at −20 °C overnight.
Fixed cells were covered with 5 μg/ml PI (Sigma-Aldrich)
and 200 μg/ml RNase A (Sigma-Aldrich) in 0.4 ml
phosphate-buffered saline for 2 h at room temperature in
the dark. Measurements were performed on a slide-based
iCys Research Imaging Cytometer (CompuCyte Corpor-
ation, Westwood, MA, USA). The DNA dye was excited
by the 488 nm laser line and emission was collected in the
red channel with a 650 nm longpass filter on a linear scale.
Single cells were recognized according to their size and
circularity and cells were further gated according to their
integral fluorescence intensity and maximum pixel inten-
sity on a two-dimensioanl scattergram of PI signal. Data
from the one-dimensional histogram of the DNA staining
was exported and fitted with the automatic one cycle dip-
loid model of the Modfit LT 3.0 software (Verity Software
House) with AutoDebris compensation, AutoAggregate
Compensation, and Apoptosis Model. In the measure-
ments, the G1–G2 linearity ratio was around 1.8 and the
RCS (Reduced Chi-Square, a measure of goodness of fit)
was less than 5. Measurements were repeated three times
and approximately 1000–2000 cells were collected from
each well.
Czimmerer et al. Genome Medicine  (2016) 8:63 Page 5 of 22
Apoptosis assay
Raw264.7 cells were plated and treated in a similar man-
ner as for the cell cycle analysis. Annexin V-FITC/PI
staining was performed as previously described [56] with
minor modifications. Forty-eight hours following miRNA
transfection, the culture medium was replaced by 100 μl
AB buffer (140 mM NaCl and 2.5 mM CaCl2), 10 μl
Hoechst 33342 solution (50 μg/ml stock), and 10 μl propi-
dium iodide solution (50 μg/ml stock) and 5 μl FITC-
conjugated annexin V (AV) was added (according to the
description of the MBL Apoptosis Detection Kit) for
15 minutes at 37 °C. Laser-scanning cytometric measure-
ments were made using a iCys Research Imaging Cyt-
ometer (CompuCyte Corporation, Westwood, MA, USA).
Hoechst, which stains all cells, was excited at 405 nm and
detected with a 463/20 bandpass filter; PI, which stains
dead cells, was excited at 488 nm and detected with a
650 nm longpass filter; and the AV signal, which indicates
apoptotic cells, was excited at 488 nm and detected with a
530/30 bandpass filter. Single cells were selected by size
and circularity and additionally gated by their DNA con-
tent. Early apoptotic AV+/PI−, late apoptotic AV+/PI+, and
unapototic AV−/PI− cells were detected using a quadrant
gate in the PI versus AV dot plot with respect to unlabeled
and miRNA untreated cells.
Plasmid construction
PsiCHECK2 dual luciferase vector (Promega) was used to
confirm the function of the putative miR-342-3p binding
sites in the Bcl2l1 3′ UTR. For luciferase reporter assays,
320 bp (miR-342-3p_1) and 309 bp (miR-342-3p_2) of the
3′ UTR of the Bcl2l1 gene, including the mir-342-3p tar-
get sites, were amplified by PCR using F1/R1 and F3/R3
primer pairs with XhoI and NotI sites. PCR was per-
formed on mouse macrophage-derived genomic DNA.
The XhoI/NotI-digested PCR product was cloned into the
XhoI/NotI-digested psiCHECK2 dual luciferase vector.
F1/R2 and F2/R1 as well as F3/R4 and F4/R3 primers were
used to delete the mir-342-3p target sites from the 3′
UTR. After mixing the two PCR products and digestion
with XhoI and NotI, the 3′ UTR fragment with deleted
mir-342-3p binding sites was cloned into a XhoI/NotI-
digested psiCHECK2 vector. Primer sequences are given
in Additional file 2.
Luciferase assay
Luciferase assays were performed as described previously
[57]. Brifely, HEK293 cells were grown on 24-well plates
to 70–80 % confluence. Transfection was performed using
PEI with 0.1 μg of pRL-TK (Rr-luc) containing 3′ UTR
sequences and 0.1 μg of pGL3 control vector (Pp-luc)
(Promega) for either a specific miR-342 or small interfer-
ing RNA control. Cell lysates were collected 30–36 h
post-transfection and luciferase activity was determined
using a Dual-Luciferase® Reporter Assay System (Pro-
mega, Mannheim, Germany). Renilla luciferase activity
was normalized to firefly luciferase activity for each cell
culture well and averaged across six well repetitions per
condition.
Statistical analysis
The two-tailed Student’s t-test was used to evaluate
the significance of the differences between two groups;
p values <0.05 were considered significant.
Results
Identification of the human alternatively activated
macrophage-specific miRNA signature
In order to determine which miRNAs are expressed in hu-
man monocytes and differentiating macrophages in the
presence of IL-4, CD14+ monocytes were separated from
human peripheral blood and exposed to IL-4 for 12 or
72 h then subjected to microarray analysis in triplicate
(the experimental design is shown in Additional file 3a).
IL-4-induced expression of markers characteristic of alter-
native macrophage activation was confirmed by RT-qPCR
and flow cytometry in human macrophages (Additional
file 4a, b). Principal component analysis of microRNomes
showed clear separation of monocytes from different
stages of macrophage differentiation (Fig. 1a). In addition,
alternative activation caused a moderate shift in the global
macrophage microRNome at 72 h following IL-4 stimula-
tion (Fig. 1a). Taken together, these results suggest that
differentiation status and cytokine treatment correlate
with distinct and characteristic miRNA expression profiles
during human monocyte-derived macrophage differenti-
ation. Next, we identified those miRNAs that were differ-
entially regulated (FDR <0.1) 72 h after IL-4 treatment; 54
miRNAs showed significant IL-4-dependent regulation
(33 upregulated and 21 downregulated; Fig. 1b; Additional
file 5). We decided to further characterize two upregulated
and two downregulated miRNAs. The selection was based
on two criteria: (i) the miRNA expression level in IL-4-
stimulated or control macrophages; and (ii) the published
miRNA-associated functions. We examined miR-193b
and miR-342-3p as two of the highly expressed IL-4-
induced miRNAs. The IL-4-dependent induction of mir-
193b expression is known, hence we used it as an ad-
equate control of our differentiation method [24]. The
other selected IL-4-enhanced miRNA, mir-342-3p, is
associated with pro-apoptotic and anti-proliferative
functions in different tumor types; it may, therefore, be
a potential negative feedback regulator of IL-4-induced
macrophage proliferation [11, 27, 58, 59]. Finally, we
chose two members of the miR-99b-125a miRNA
polycistron, including miR-99b and miR-125a-5p,
where IL-4 was able to reduce the dramatic human
monocyte–macrophage transition-dependent induction
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of miRNA expression. The expression changes of
these miRNAs were validated using stem-loop RT-
qPCR in monocytes as well as macrophages from four
independent donors that were left unstimulated or
differentiated with IL-4 (Fig. 1c; Additional file 6a).
The expression of miR-342-3p was unchanged while
miR-193b expression was slightly induced during the
monocyte-to-macrophage transition, while both increased
significantly in response to IL-4. In contrast, miR-99b and
miR-125a-5p showed a significant induction during
A
C
B
Fig. 1 The IL-4 regulated microRNome in human alternatively activated macrophages. a Two-dimensional principle component analysis of the miRNA
transcriptome of human peripheral blood-derived monocytes, as well as unstimulated and IL-4-stimulated differentiated macrophages obtained from
three independent donors. Principal component analysis was carried out on all miRNAs expressed in monocytes and/or macrophages (500 miRNAs).
Color scheme: monocytes (Mo.), red; 12-h nontreated (nt.) differentiating macrophages, blue; 12-h IL-4 stimulated differentiating macrophages, light
green; 72-h nontreated macrophages, dark green; and 72-h IL-4-stimulated macrophages, orange. b Heatmap showing average fold changes and
significance of the top ten IL-4 upregulated and downregulated miRNAs (FDR ˂0.1) in 72-h unstimulated macrophages compared with monocytes
(left panel) and 72-h IL-4-treated macrophages compared with 72-h unstimulated macrophages (right panel) from three independent human donors.
c Stem-loop RT-qPCR-based measurement of miR-342-3p, miR-193b, miR-99b, and miR-125a-5p expression in human monocytes, 72-h nontreated,
and IL-4-stimulated macrophages. Bars show the mean ± standard deviation of normalized signal intensity values from four independent human
donor-derived cells. *P ˂ 0.05, **P ˂ 0.01, ***P ˂ 0.001; n.s. not significant
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monocyte–macrophage differentiation. In addition, miR-
99b and miR-125a-5p expression were attenuated in IL-4-
stimulated macrophages in all four human donors, al-
though the IL-4-dependent reduction of mir-99b ex-
pression did not reach statistical significance (p = 0.056)
(Fig. 1c; Additional file 6a).
Conserved IL-4Rα/STAT6 signaling-dependent regulation
of miR-342-3p, miR-99b, and miR-125a-5p expression
during in vitro and in vivo mouse alternative macrophage
activation
Next we asked if the identified IL4-dependent miRNAs
(Fig. 1c) were regulated in an evolutionarily conserved
manner between human and mouse. We therefore
measured their expression in mouse bone marrow-
derived macrophages (BMDMs) undergoing alternative
macrophage activation using stem-loop RT-qPCR (the
experimental design is shown in Additional file 3b).
Alternative activation of mouse BMDMs was con-
firmed by flow cytometry and RT-qPCR-based mea-
surements of known murine alternative macrophage
activation markers and by assessment of arginase
activity (Additional file 4c–e). As shown in Fig. 2a,
miR-342-3p, miR-99b, and miR-125a-5p were regu-
lated by IL-4 similar to the human cells. In contrast,
miR-193b expression did not change upon IL-4 treat-
ment. These findings suggest that the IL-4-mediated
regulation of miR-342-3p, miR-99b, and miR-125a-5p
is conserved between humans and mice.
In order to determine if the IL-4-mediated changes of
miRNA expression measured in vitro also occur in vivo,
we applied a mouse model of alternative macrophage ac-
tivation. As described previously, intraperitoneal im-
plantation of the filarial nematode B. malayi results in
the accumulation of macrophages with M2-like charac-
teristics, including elevated expression of Ym1, Fizz1/
RELM-α, and Arg1 [7, 60]. Based on this, we determined
miR-342-3p, miR-99b, and miR-125a-5p expression in
nematode-elicited macrophages at different time points
after infection (the experimental design is shown in
Additional file 3c). In line with our in vitro results, miR-
342-3p expression was upregulated in nematode-elicited
macrophages 3 days after B. malayi implantation com-
pared with naïve cells and showed continuously decreas-
ing kinetics at later time points (Fig. 2b). Furthermore,
both miR-99b and miR-125a-5p showed reduced expres-
sion during B. malayi-induced alternative macrophage
activation, also reinforcing our in vitro findings (Fig. 2b).
These results suggest that the conserved IL-4-dependent
regulation of miR-342-3p, miR-99b, and miR-125a-5p
expression holds in vivo relevance. Therefore, we focused
our efforts on the identification of the upstream regula-
tor(s) of miR-342-3p, miR-125a, and miR-99b expression
during mouse alternative macrophage activation. In mac-
rophages, IL-4 acts via IL-4Rα-containing type I and II
A
B
Fig. 2 Conserved miRNA expression in mouse in vitro and in vivo differentiated and alternatively activated macrophages. a Stem-loop
RT-qPCR-based measurement of miR-342-3p, miR-193b, miR-99b, and miR-125a-5p expression in IL-4-stimulated and unstimulated mouse
bone marrow-derived macrophages. Each data point represents the mean and standard deviation of three individual animals. *P ˂ 0.05,
**P ˂ 0.01; ns. not significant. b Stem-loop RT-qPCR-based quantification of miR-342-3p, miR-99b, and miR-125a-5p in mouse thioglycolate-elicited and
in vivo alternatively activated macrophages. Each data point represents the mean and standard deviation of five individual animals. *P ˂ 0.05, **P ˂ 0.01,
***P ˂ 0.001; ns. indicates not significant
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receptor complexes [6]. As expected, we found that both
the IL-4-mediated induction of miR-342-3p as well as the
reduction of miR-99b and miR-125a-5p expression were
completely abolished in IL-4Rα-deficient macrophages,
confirming the requirement of the receptor for transmit-
ting the IL-4 stimulus (Fig. 3a). IL-4 receptor complexes
activate both the JAK/STAT6 and PI3K signaling path-
ways [6]. Since STAT6 transcription factor has been
shown to be the dominant mediator of IL-4-induced tran-
scriptional changes in macrophages [6], we hypothesized
that STAT6 might be primarily responsible for the IL-4-
induced changes in the macrophage microRNome. In
order to assess the contribution of STAT6 to the regula-
tion of the IL-4-responsive miRNAs, we analyzed the
microRNome of WT and STAT6-deficient macrophages
in the absence and presence of IL-4. We found that the
majority of IL-4-responsive miRNAs in WT macrophages
were STAT6-dependent (151 from 157; Fig. 3b; Additional
file 7). Interestingly, we found only 11 miRNAs that
showed changed expression upon IL-4 stimulus in
STAT6-deficient macrophages (Fig. 3b; Additional files 7
and 8a). The IL-4-induced upregulation of miR-342-3p
and downregulation of miR-99b and miR-125a-5p proved
to be STAT6-dependent, which was also validated by
stem-loop RT-qPCR (Fig. 3c). Taken together, these find-
ings suggest that these miRNAs are regulated exclusively
via the IL-4Rα/STAT6 signaling axis during alternative
macrophage activation.
Direct Stat6-dependent induction of miR-342-3p and its
host gene, EVL, during alternative activation of murine
and human macrophages
Intronic miRNAs and their host genes are often co-
regulated, although there are known instances when in-
tronic miRNAs are regulated by their own promoter re-
gion independently of that of the host gene [61, 62].
A
B
C
Fig. 3 IL-4Rα and Stat6-dependency of IL-4-regulated miRNA expression in mouse macrophages. a miR-342-3p, miR-99b, and miR-125a-5p
expression in IL-4-stimulated or unstimulated wild-type (WT) and IL-4Rα-defficient (IL-4Rα KO) mouse bone marrow-derived macrophages as
measured by stem-loop RT-qPCR. Each data point represents the mean and standard deviation of four or three (WT or IL-4Rα KO, respectively)
individual animals. *P ˂ 0.05, **P ˂ 0.01, ***P ˂ 0.001. b The number of miRNAs showing significant (FDR ˂0.1) IL-4-dependent regulation in
wild-type (WT) and Stat6-deficient (STAT6 KO) macrophages. c Stem-loop RT-qPCR-based quantification of miR-342-3p, miR-99b, and miR-125a-5p
expression in IL-4-stimulated or unstimulated WT and Stat6 KO mouse bone marrow-derived macrophages. Each data point represents the mean
and standard deviation of three individual animals. *P ˂ 0.05, **P ˂ 0.01, ***P ˂ 0.001
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miR-342-3p is encoded within the third intron of the
EVL gene in humans and mice and its expression
showed coordinated regulation in both human colorectal
cancer and multiple myeloma [63, 64]. Therefore, we de-
cided to further characterize the potential regulatory
mechanism controlling the expression of the host gene
and the miRNA during human and mouse alternative
macrophage activation. For this reason we analyzed pub-
licly available GRO-seq data from unstimulated and
ChIP-seq datasets from both IL-4-stimulated and un-
stimulated mouse macrophages [65, 66].
Combined analysis of transcription of nascent RNA
(GRO-seq) and the location of the active transcription
start site (TSS)-specific histone mark H3K4m3 (ChIP-
seq) data showed that the shortest known transcript
variant of Evl (NM_001163396) was transcribed in rest-
ing mouse macrophages (Fig. 4a). Furthermore, the
H3K4m3 histone modification was increased at the TSS
of Evl in IL-4-stimulated macrophages compared with
unstimulated cells (Fig. 4a). Interestingly, the H3K4m3
peak was not detected in the intronic region of Evl
around the miR-342-3p coding region, suggesting that
Evl and miR-342-3p utilized a common TSS in resting
and alternatively activated mouse macrophages (Fig. 4a).
To further explore the IL-4-dependent regulation of
miR-342-3p and Evl in mice, we measured the expres-
sion of both mature miRNA and its host gene in mouse
bone marrow cells as well as in IL-4-stimulated and un-
stimulated BMDMs. Both Evl and miR-342-3p expression
levels were induced during mouse BMDM differentiation,
which was further increased by IL-4 in a STAT6-
dependent manner (Fig. 4b, c).
Moreover, we examined the macrophage lineage-
specific transcription factor Pu.1 and IL-4-activated
STAT6 binding at the predicted EVL-associated func-
tional domain/chromatin loop. First, CTCF and Rad21
ChIP-seq data sets from unstimulated macrophages were
used for the functional domain/chromatin loop predic-
tion. Functional chromatin domains were defined using
the following criteria: (i) common CTCF and Rad21
binding at the starting points of chromatin interactions;
and (ii) a predominantly convergent direction of the
CTCF elements under CTCF/Rad21 co-peaks [67–70].
One distinct Evl-associated putative functional domain
(loop) was predicted using these features (Fig. 4a). Next,
Pu.1-bound genomic regions were identified and exam-
ined within the predicted functional domain in both
unstimulated and IL-4-treated macrophages but Pu.1-
binding was not influenced by IL-4 stimulation (Fig. 4a).
In addition, IL-4-induced Stat6 peaks were detected both
upstream and downstream of the TSS of the Evl gene in
mouse macrophages [65] (Fig. 4a).
Next we validated two Stat6-bound genomic regions
−4 kb (mEvl_Stat6 site A) and +4 kb (mEVL_Stat6 site
B) from the TSS. ChIP followed by qPCR showed an en-
richment of Stat6 binding at these sites in IL-4-
stimulated WT macrophages relative to untreated WT
and IL-4-treated Stat6-deficient macrophages as well as
IgG controls (Fig. 4d). These are the likely enhancers
controlling Evl as well as miR-342-3p induction. In order
to determine whether IL-4-mediated co-regulation of
EVL and miR-342-3p is conserved between human and
mouse, we measured their expression in human
monocyte-derived unstimulated and IL-4-stimulated
macrophages. As shown in Fig. 4e and Additional file
6b, IL-4 induced EVL expression in all three donors after
12 h, which then was reduced at later time points. miR-
342-3p followed similar but delayed kinetics upon IL-4
treatment as its elevated expression was only detectable
after 24 h (Fig. 4f; Additional file 6c). In order to assess
whether STAT6 binds the genomic locus of human EVL,
we utilized public human STAT6 ChIP-seq datasets from
IL-4 stimulated Th2-type T cells [71]. Interestingly, a
genomic region within +0.3 kb of the TSS of the EVL
gene was occupied by STAT6 in these cells. Therefore,
we hypothesized that this region might also be occupied
by STAT6 in human alternatively activated macrophages.
This could be confirmed by ChIP-qPCR in two inde-
pendent donors (D1 and D2; Fig. 4g). These findings
suggest that miR-342-3p and its host gene, EVL, are co-
ordinately regulated by IL-4 via direct DNA binding of
STAT6 in both mouse and human macrophages.
Alternative macrophage activation-specific repression of
the miR-99b-125a miRNA polycistron is mediated at the
transcriptional level by IL-4/STAT6 signaling
Similarly to the analyses described above (Fig. 4a), we
took advantage of publicly available GRO-seq datesets
from unstimulated as well as ChIP-seq datasets from IL-
4-stimulated and unstimulated mouse macrophages [65]
to identify the primary transcripts coding miR-99b and
miR-125a and further investigate the regulation of miR-
99b and miR-125a expression. We identified only one
overlapping H3K4m3 peak with a divergent GRO-seq
signal, a hallmark of an active enhancer, downstream of
the miR-99b and miR-125a-coding genomic region, con-
firming the common TSS and polycistronic transcription
of miR-99b and miR-125a (Fig. 5a). In order to deter-
mine whether IL-4 represses miR-99b and miR-125a
expression at the transcriptional or mRNA maturation
level, we measured the expression of both primary (pri-
miR-99b-125a) and mature transcripts in mouse bone
marrow as well as IL-4-stimulated or unstimulated
BMDMs (the genomic localization of the pri-miR-99b-
125a-specific primer pair is shown in Additional file 9).
miR-99b, miR-125a-5p, and pri-miR-99b-125a expres-
sion levels were increased to a similar extent in
BMDMs compared with the bone marrow cells (Fig. 5b).
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Fig. 4 Mechanism of IL-4-dependent co-regulation of miR-342-3p and EVL expression in human and mouse macrophages. a Strand-specific
GRO-Seq, CTCF, and Rad21-specific ChIP-seq signals in unstimulated as well as H3K4m3, H3K4m1, H3K27Ac, Pu.1, and Stat6 ChIP-Seq signals in
IL-4-stimulated and unstimulated mouse macrophages at the EVL locus visualized by the Integrative Genomics Viewer. b RT-qPCR-based
measurement of Evl expression in bone marrow (BM) cells and IL-4 stimulated or unstimulated bone marrow-derived macrophages (BMDM)
in wild-type (WT) or Stat6-deficient (Stat6 KO) mice. Each data point represents the mean and standard deviation (SD) of three individual animals.
**P ˂ 0.01. c Stem-loop RT-qPCR-based quantification of miR-342-3p expression in bone marrow cells and IL-4 stimulated or unstimulated bone
marrow-derived macrophages in WT or Stat6 KO mice. Each data point represents the mean and SD of three individual animals. **P ˂ 0.01.
d IL-4-induced Stat6 binding of two regulatory regions of the mouse EVL gene in WT and Stat6 KO mouse macrophages measured by
ChIP-qPCR. Columns represent mean arbitrary units described in the “Methods” section ± SD. e RT-qPCR-based measurement of EVL expression during
human macrophage differentiation in the absence or presence of IL-4 (a representative example of three independent human donors is shown).
f Stem-loop RT-qPCR-based quantification of miR-342-3p expression during human macrophage differentiation in the absence or presence of IL-4
(a representative example of three independent human donors is shown). g IL-4-induced recruitment of STAT6 to the human EVL (hEVL) locus in
macrophages obtained from two independent human donors (D1 and D2) measured by ChIP-qPCR. Data are expressed as mean ± SD
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Furthermore, IL-4 was able to reduce the expression of
both pri-miR-99b-125a and the mature miRNAs in
BMDMs compared with untreated cells (Fig. 5b). As
shown in Fig. 3b, IL-4-mediated negative regulation of
mature miR-99b and miR-125a-5p expression proved
to be Stat6-dependent in mouse macrophages; hence,
it was logical to assume that IL-4 represses the primary
miRNA in a similar manner. Therefore, the expression
level of pri-miR-99b-125a was measured in IL-4-stimu-
lated and unstimulated BMDMs derived from WT and
Stat6-deficient mice. We found that IL-4-dependent re-
pression of pri-miR-99b-125a was completely abolished in
A
B
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Fig. 5 IL-4-dependent and Stat6-mediated repression of the miR-99b-125a miRNA polycistron. a Strand-specific GRO-Seq, CTCF, and
Rad21-specific ChIP-seq signals in unstimulated as well as H3K4m3, H3K4m1, H3K27Ac, Pu.1, and Stat6 ChIP-Seq signals in IL-4-stimulated
and unstimulated mouse macrophages at the miR-99b-125a and Spaca6 loci visualized by the Integrative Genomics Viewer. b Pri-miR-99b-
125a, miR-99b, and miR-125a-5p expression in bone marrow cells (BM), MCSF, and MCSF + IL-4-treated BMDMs. Each data point represents the mean
and standard deviation (SD) of three individual animals. *P ˂ 0.05, **P ˂ 0.01. c Expression of the pri-miR-99b-125a polycistron in IL-4-stimulated or
unstimulated BMDMs derived from wild-type (WT) or Stat6-defficient (Stat6 KO) mice. Each data point represents the mean and SD of three individual
animals. *P ˂ 0.05. d H3K27Ac ChIP-qPCR in IL-4-treated or nontreated WT or Stat6 KO mouse BMDMs at the potential TSS of pri-miR-99b-125a. Data
are expressed as mean ± SD. e RT-PCR-based detection of a common transcript of pri-miR-99b-125a and Spaca6 in IL-4-treated or nontreated WT
mouse BMDMs. Cyclophilin A (cyclo) serves as normalization control
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the absence of Stat6 (Fig. 5c), suggesting that Stat6 is the
key transcriptional mediator of the IL-4-dependent re-
pression of miR-99b and miR-125a-5p expression. In
order to determine the direct regulatory role of the
lineage-specific transcription factor Pu.1 and the signal-
specific transcription factor STAT6 in the IL-4-mediated
repression of pri-miR-99b-125a expression, we sought to
identify the Pu.1 and STAT6-bound genomic regions
using resting and IL-4-stimulated, macrophage-derived,
publicly available ChIP-seq dataset [65].
However, Pu.1- and Stat6-binding activity could not be
detected within the predicted functional domain of pri-
miR-99b-125a. These findings suggest that although the
IL-4-mediated regulation of miR-99b and miR-125a ex-
pression is STAT6-dependent, (i) it might not be regu-
lated via direct STAT6 DNA binding or (ii) the
regulatory region might be outside of that explored
within this study (Fig. 5a). Interestingly, H3K27 acetyl-
ation (the active histone mark) of the TSS of pri-miR-
99b-125a was IL4-dependently reduced in WT but not
in STAT6-deficient BMDMs (Fig. 5a, d), which further
suggests that IL-4 represses transcription of the miR-
99b-125a polycistron in a STAT6-dependent manner.
In addition, we found nascent RNA transcription at
the genomic locus of the neighboring Spaca6 gene, al-
though no H3K4m3 peak was detected at the 5′ end of
this gene (Fig. 5a). Based on this observation, we hy-
pothesized that the miR-99b-125a polycistron and
Spaca6 might have common primary transcripts in mac-
rophages. In order to test this, we used RT-PCR assays
in which the PCR primers detected both miR-125a and
the first predicted exon of Spaca6 (the genomic
localization of a common pri-miR-99b-125a and Spaca6-
specific primer pair is shown in Additional file 9). As
shown in Fig. 5e, the expected 440-nucleotide PCR
product was present in untreated macrophages and IL-4
treatment reduced the expression of this transcript
(Fig. 5e). These findings suggest that the miR-99b-125a
polycistron and Spaca6 form one STAT6-regulated tran-
scription unit and they are encoded by the same primary
transcript.
miR-342-3p regulates cell proliferation and apoptosis-
associated signaling pathways at the post-transcriptional
level in macrophages
In order to gain insights into the molecular pathways
controlled by miR-342-3p, we examined the transcrip-
tome of miR-342-3p-transfected RAW264.7 macro-
phages and identified a set of repressed miR-342-3p
direct target genes using computational and biochemical
approaches (a flowchart of experimental approaches is
shown in Fig. 6a). Microarray analysis of miR-342-3p
and miR-negative control-transfected cells identified
2640 downregulated and 2341 upregulated genes (FDR
<0.1) in miR-342-3p-overexpressing macrophages com-
pared with negative control-transfected cells (Fig. 6a;
Additional file 10). To identify those biological functions
whose activity might be regulated by miR-342-3p, we
analyzed the list of the most significantly regulated genes
(FDR ≤0.01) using the ClueGO Cytoscape plugin [72].
We found that the significantly overrepresented miR-342-
3p-regulated Gene Ontology (GO) categories included
cellular metabolism and regulation of viable cell number,
including cell proliferation and cell death (Fig. 6b). In
addition, Sylamer analysis of the microarrays derived from
miR-342-3p and miR-negative control-transfected cells
showed that the complementary sequence of the 8-mer
seed region of miR-342-3p was enriched within the 3′
UTR of downregulated genes in miR-342-3p-trans-
fected cells, confirming the specificity of the miR-342-
3p-induced transcriptomic changes (Fig. 6c). For the
identification of functionally important miRNA–mRNA
interactions we used a new TargetExpress method
(manuscript submitted; see “Methods”) that combines
TargetScan [49] and microT-CDS [50] predictions with
the gene expression profile of the negative control condi-
tion. The resulting predicted miR-342-3p targets showed
the best correlation with miR-342-3p-dependent repression
of gene expression in our experimental system (Fig. 6d);
813 predicted miR-342-3p target genes were downreg-
ulated in pre-miR-342-3p-transfected cells (Fig. 6a;
Additional file 11). These findings raise the possibility
that these downregulated genes are repressed directly
by miR-342-3p. However, further experimental con-
firmation is required for the demonstration of direct
miR-342-3p-dependent repression.
miR-342-3p acts as a regulator of macrophage cell
number via reduction of cell viability and induction of
apoptosis
Our transcriptome analysis revealed cellular prolifera-
tion and cell death as major target processes regulated
by miR-342-3p. Proliferation of local macrophage popula-
tion is induced by IL-4-mediated Th2-type inflammation
[27]. Furthermore miR-342-3p has been described to be
aberrantly downregulated in different malignancies, in-
cluding colorectal and breast cancers [58, 63]. In addition,
overexpression of miR-342-3p was found to induce apop-
tosis and block cancer cell proliferation [59, 63]. Thus, we
hypothesized that IL-4-induced miR-342-3p expression
could be a potential negative feedback mechanism con-
trolling excessive macrophage expansion upon Th2-type
cytokine stimulus.
In order to test this hypothesis, we sought to explore
the functional effect of miR-342-3p on macrophage pro-
liferation and/or apoptosis in the mouse macrophage cell
line RAW264.7 transfected with miR-342-3p or miR-
negative control miRNA mimics. Following transfection,
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cell numbers were determined at various time points by
propidium iodide (PI) staining of permeabilized adherent
cells [53]. The cell number of miR-342-3p-overexpressing
macrophages showed 40 and more than 80 % reduction at
24 and 48 h post-transfection, respectively, compared with
the miR-negative control-transfected cells (Fig. 7a). To
confirm our results, resazurin reduction and neutral red
uptake-based assays as independent in vitro cell viability
Fig. 6 Global transcriptome and in silico analysis-based miR-342-3p target gene identification. a Schematic representation of combined
microarray-based and computational miR-342-3p target gene identification. b Network visualization of Gene Ontology enrichment analysis of
genes differentially expressed in miR-342-3p-transfected RAW264.7 mouse macrophages (FDR ≤0.01) using the ClueGO Cytoscape plugin. Nodes
represent enriched GO biological process terms, node colors represent corresponding FDR values (Benjamini-Hochberg method), and node sizes
represent the number of genes associated with the GO term. Only the label of the most significant term per group is shown. Nodes without
second degree connections are omitted for clarity. c Sylamer analysis revealed that only miR-342-3p 8-mer seed matches were enriched among
downregulated genes in miR-342-3p-transfected macrophages compared with miR-negative control-treated cells. miR-342-3p and murine miRNA
seed matches are represented as red dashed lines and gray lines, respectively. d Cumulative distributions of relative change (t-statistic) for different
sets of potential miR-342-3p target genes with 7mer.1A (blue), 7mer.m8 (green), and 8-mer (red) seeds or the top 1000 TargetScan (orange) or
microT-CDS (purple) and TargetExpress (brown) predictions to be functionally downregulated. Set size and the statistical significance of each set
being more repressed than genes with no potential target site are shown in parentheses
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Fig. 7 Reduced cell viability and increased macrophage apoptosis by miR-342-3p overexpression. a PI staining-based cell number analysis of
RAW264. Seven cells at different time points following miR-342-3p mimic transfection. Each data point represents the mean and standard error of
the mean (SEM) of five parallel samples from two independent experiments. *P ˂ 0.05, **P ˂ 0.01. b Neutral red-based cell viability analysis of miR
negative control (miR-neg) and miR-342-3p (miR-342-3p) mimic-transfected RAW264.7 cells 48 h after miRNA mimic transfection. Each data point
represents the mean and SEM of four independent experiments. *P ˂ 0.05. c Resorufin-based cell viability analysis of miR-negative control and
miR-342-3p mimic-transfected RAW264.7 cells 48 h after miRNA mimic transfection. Each data point represents the mean and SEM of four
independent experiments. *P ˂ 0.05. d Effect of miR-342-3p on cell cycle progression in RAW264.7 cells. Cell cycle distribution was evaluated by
slide-based imaging cytometry after PI staining. Each data point represents the mean and standard deviation (SD) of three independent experiments.
*P ˂ 0.05. e Representative dot plots of laser-scanning imaging cytometry analysis of AV- and PI-labeled miR negative control and miR-342-3p
mimic-transfected RAW264.7 cells 48 h after miRNA mimic transfection. f Viable (PI-, AV-), early apoptotic (PI-, AV+) and late apoptotic (PI+, AV+) cell
distribution 48 h following miR-negative control and miR-342-3p mimic transfection into RAW264.7 cells. Each data point represents the mean and SD
of three independent experiments. *P ˂ 0.05
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analyses were also carried out [54]. As shown in Fig. 7b, c,
miR-342-3p reduced viable macrophage cell numbers by
40 and 55 % at 48 h post-transfection in the resazurin and
neutral red uptake assays, respectively. In order to assess
if the decreased cell viability observed is the result of im-
paired progression of the cells through the cell cycle or is
due to increased cellular death, we performed cell cycle
analysis by PI staining and a necrosis/apoptosis assay by
annexin V (AV)/PI double-staining of the miR-342-3p and
miR-negative control-transfected macrophages. As shown
in Fig. 7d, analysis of cell cycle distribution by Hoechst
staining and slide-based imaging cytometry revealed that
miR-342-3p overexpression was associated with a slight
but not significant increase in the number of cells in S
phase. However, miR-342-3p overexpression significantly
increased the number of both AV-positive/PI-negative
early (Fig. 7e, lower right quadrants) and AV/PI double
positive late (Fig. 7e, upper right quadrants) apoptotic cells
(Fig. 7e, f ). From these results we concluded that miR-
342-3p regulates macrophage cell numbers via induction
of apoptosis.
Interestingly, the gene set of downregulated potential
miR-342-3p target genes contained 23 genes from the GO
category “negative regulators of apoptosis” (GO:0043066;
Fig. 8a). We used GeneMANIA to investigate the poten-
tial interactions between the miR-342-3p-repressed anti-
A
C
B
Fig. 8 miR-342-3p-repressed anti-apoptotic gene network in macrophages. a Relative expression heatmap of selected potential anti-apoptotic
miR-342-3p target gene expression in miR-negative control (miR-neg) and miR-342-3p-overexpressing RAW264.7 cells 18 h after miRNA mimic
transfection in three independent experiments (significance of repression is indicated after the gene name: *FDR ≤0.1, **FDR ≤0.05, ***FDR
≤0.01). b GeneMANIA-based identification of the miR-342-3p-repressed, anti-apoptotic gene network. c Luciferase activity in HEK293T cells cotransfected
with luciferase expression constructs containing WT or mutated (Del) miR-342-3p binding sites of Bcl2l1 and miR-342-3p/miRNA negative-control mimics
(n = 6). *P ˂ 0.05, ns. not significant
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apoptotic genes and found that 19 out of 23 predicted
miR-342-3p target genes formed an anti-apoptotic gene
network showing extensive predicted interactions and
colocalization [73] (Fig. 8b). To explore the direct
miRNA–mRNA interactions, we selected Bcl2l1 as one
of the central components of the miR-342-3p-regulated
anti-apoptotic gene network for further analysis. In
silico analysis using the TargetScan target prediction al-
gorithm showed two predicted mir-342-3p binding sites
within the 3′ UTR of Bcl2l1 (Fig. 8c, miR-342-3p_I and
miR-342-3p_II) [74]. We generated luciferase expression
constructs with the predicted miR-342-3p-containing 3′
UTR regions of Bcl2l1 or mutated versions (Fig. 8c). The
mutated constructs contained a nine-nucleotide deletion
of miR-342-3p binding regions. We cotransfected the gen-
erated luciferase expression constructs with miR-342-3p
and miRNA-negative control mimics into HEK293T cells.
Small but statistically significant repression was observed
in the luciferase activity of the miR-342-3p_I binding site-
containing construct in the presence of the miR-342-3p
mimic compared with the miR-negative control (Fig. 8c).
miR-342-3p mimic-dependent reduction of luciferase ac-
tivity was completely abolished when the miR-342-3p_I
binding site was deleted (Fig. 8c). In contrast, the lucifer-
ase activity of the construct containing the miR-342-3p_II
binding site was not affected significantly by miR-342-3p
overexpression. To further examine the specificity of the
luciferase assay system we used, we performed two control
experiments. First, we detected no activity of the miR-
342-3p mimic on the 3′ UTR of Ago2, which does not
contain a miR-342-3p binding site. In addition, we did not
detect any activity of miR-184 and miR-375 on the 3′
UTR of Bcl2l1-1, which lacks recognition sequences for
these control miRNAs (Additional file 12). Taken together,
the combination of our in silico and experimental ap-
proaches suggest the miR-342-3p-dependent repression of
Bcl2l1 expression, however, the demonstration of direct
regulation requires further analysis.
Discussion
Many Th1- and Th2-type inflammation-linked miRNAs,
including miR-155, miR-146, and miR-324-5p, appear to
be conserved in both mouse and human macrophages
and are induced by LPS or IL-4, suggesting that the
regulation of miRNA expression and function during
classic or alternative macrophage activation is conserved
[15, 18, 20, 24, 75].
Our data presented here suggest that additional con-
served miRNAs exist in alternatively activated macro-
phages. We studied the regulation of miR-342-3p, miR-
99b, and miR-125a-5p expression during IL-4-induced
differentiation in vitro in human and murine macro-
phages as well as in nematode implantation-induced
alternatively activated murine macrophages in vivo. We
found that macrophage-specific, IL-4-dependent regu-
lation of these miRNAs showed conserved regulation in
human and mouse. It has been previously shown that
these miRNAs are expressed in myeloid cells and par-
ticipate in the regulation of macrophage phenotype, but
their function in alternative macrophage activation has
not been described before [24, 76–80].
miR-125a and miR-125b, containing the same seed se-
quences, are induced during classical macrophage activa-
tion and potentiate M1 polarization through direct
inhibition of anti-inflammatory Tnfaip3 (A20) and Irf4 ex-
pression [24, 81, 82]. Intriguingly, we found that miR-125a
expression is reduced during alternative macrophage acti-
vation both in vitro and in vivo. It has been previously de-
scribed that the common miR-125a/miR-125b target gene
Irf4 facilitates M2 macrophage polarization and host re-
sponse against helminth infection [83, 84]. In addition,
several target prediction algorithms predict Irf4 as a direct
target gene of miR-99b. These data raise the possibility
that decreased miR-125a and miR-99b levels might con-
tribute to alternative macrophage activation by leading to
increased Irf4 expression. However, miR-125b shows op-
posite regulation during in vitro and in vivo alternative
macrophage activation, though regulation of miR-125b ex-
pression was not studied at early time points of nematode
infection-induced M2 macrophage activation [19]. These
findings collectively suggest a complex role of miR99b,
miR-125a, and miR-125b in the regulation of alternative
macrophage activation. Nevertheless, further studies are
needed to explore the time-dependent regulation and dis-
sect the exact roles of these miRNAs during M2
polarization.
IL-4 stimulation leads to the activation of both the JAK/
STAT6 and PI3K signaling pathways in myeloid cells [6].
However, it was previously unknown which pathways play
critical roles in the regulation of the macrophage micro-
RNome during IL-4-dependent alternative macrophage
activation. We observed that the majority of IL-4-
regulated miRNAs were strictly STAT6-dependent in
mouse macrophages, including miR-342-3p, miR-125a-5p,
and miR-99b-5p, as well as the previously studied miR-
511-5p and miR-324-5p. In addition, genome-wide map-
ping of Stat6-binding in IL-4-stimulated T cells showed
that activated Stat6 binds intronic and exonic regions as
well as distant enhancer regions of its target genes [71,
85]. Accordingly, we found that IL-4 induces Stat6 binding
of an adjacent genomic region of Evl in mouse and human
macrophages (+4 kb and −4 kb in mouse; +0.3 kb in hu-
man), suggesting that Evl and miR-342 are direct targets
of IL-4/Stat6 signaling in both human and murine alterna-
tive macrophage activation. Interestingly, elevated expres-
sion of miR-342-5p (derived from the 5′ strand of the pre-
miR-342 miRNA precursor) in inflammatory macrophages
has been linked to the formation of atherosclerotic lesions
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[86]. Both these results and our findings suggest that pri-
miRNA expression and miRNA strand selection may be
regulated in macrophages by different external stimuli.
Interestingly, 11 miRNAs showed IL-4-dependent regula-
tion in STAT6 deficient macrophages, suggesting the par-
ticipation of STAT6-independent signaling pathway(s) in
the regulation of these miRNAs.
Rapid macrophage accumulation is observed in different
pathological conditions, including pathogen infections and
inflammation [2]. Although the general paradigm of
macrophage accumulation is that monocytes or other
hematopoietic cells are recruited to sites of inflammation
and differentiate into macrophages [87, 88], the rapid pro-
liferation of resident macrophages in adipose tissue of
obese animals and atherosclerotic lesions was also de-
scribed recently [89, 90]. In addition, local IL-4-dependent
macrophage proliferation was observed following parasite
infections in mice [27]. Certain miRNAs responding to
external stimuli have anti-proliferative or pro-apoptotic
effects in immune or cancer cells, which may function as
a negative feedback mechanism controlling local cell pro-
liferation. Specifically, E2F1 induces cell cycle progression
but also potentiates apoptosis via upregulating pro-apop-
totic miR-449a/b expression [91]. Furthermore, Th2-type
inflammation induces macrophage proliferation and anti-
proliferative miR-378 expression simultaneously, sug-
gesting a complex regulation of in situ macrophage
proliferation [19]. miR-342-3p also has pro-apoptotic
and anti-proliferative roles in colorectal and breast
cancer cells [58, 59, 63]. We found that increased miR-
342-3p expression paralleled macrophage proliferation
changes observed at the early stage of B. malayi-induced
alternative macrophage activation, which suggests a po-
tential role of miR-342-3p in regulating the amount of
local viable macrophages [19]. Indeed, our functional
studies showed that miR-342-3p over-expression reduced
viable macrophage number via induction of apoptosis. We
identified a miR-342-3p-repressed anti-apoptotic gene
network with well characterized inhibitors of apoptosis,
including Bcl2l1, Xiap, Api5, and Birc6 in macrophages by
applying a combination of in silico target prediction algo-
rithms and miRNA mimic experiments. In addition, we
found that Bcl2l1 is directly repressed by miR-342-3p.
These findings strongly suggest a role for IL-4-induced
miR-342-3p as a potent negative feedback regulator of
macrophage cell number via induction of apoptosis.
Thus, the IL-4-triggered proliferative response of mac-
rophages might be accompanied by the simultaneous
induction of counteracting cellular processes, generat-
ing an endogenous limit of macrophage abundance.
The proposed dual role of IL-4 is further supported by
the observation that IL-4 is capable of sensitizing mac-
rophages to rapamycin-induced apoptosis [92]. Intri-
guingly, elevated expression of miR-342-3p in the liver
is accompanied by enhanced macrophage apoptosis in
malaria-infected mice [93, 94]. These results thus raise
the possibility of a connection between macrophage
apoptosis and elevated miR-342-3p expression induced
by Th2-type inflammation.
The functional plasticity of macrophages determined by
polarization signals plays an important role during the de-
velopment and progression of several human diseases, in-
cluding sepsis, malignancies, and metabolic disorders [95].
Alternatively activated macrophage-like disease-associated
macrophages are observed in the late phase of sepsis and
during tumor progression [96, 97]. In addition, an in-
creased number of alternatively activated-like tumor-
associated macrophages has been shown to be associated
with poor prognosis in several human tumors, including
prostate, cervix, breast, and bladder cancer [98]. For these
reasons, the transcriptomic and functional characterization
of disease-associated macrophages certainly has a high
clinical importance. Based on the data presented here and
published by others, macrophage-expressed miRNAs show
polarization-specific expression patterns and functions
[14–17]. The molecular stability of miRNAs in formalin-
fixed, paraffin-embedded samples makes them suitable
diagnostic and prognostic markers. Furthermore, a well
characterized alternative activation-specific marker set has
not been available before in the case of human macro-
phages [6]. Some miRNAs from our study, including miR-
342-3p and miR-193b, may be promising candidates as
potential biomarkers in combination with other well char-
acterized alternative macrophage activation-specific genes
and proteins in human diseases. Recent studies have pro-
vided strong evidence that miRNA targeting in vivo using
chemically modified oligonucleotides can alter disease out-
come in animal models. It would be interesting to examine
if in vivo overexpression of pro-apoptotic miR-342-3p has
therapeutic relevance in alternative macrophage activation-
associated human diseases, including fibrosis and certain
malignant tumors that are characterized by pathologic
macrophage abundance. However, both diagnostic and
therapeutic applications of these miRNAs require further
investigation by utilizing disease models and extensive ana-
lyses of clinical samples.
Conclusions
The aim of this study was to identify the miRNA signature
and its phenotypic consequences in human and mouse
models of alternative macrophage activation in vitro and
in vivo using a combination of transcriptomic, genomic,
bioinformatic, and functional approaches. We uncovered
a dynamically regulated miRNA expression pattern during
human monocyte–macrophage differentiation and IL-4-
mediated alternative macrophage activation. We found
that three IL-4-responsive miRNAs (miR-342-3p, miR-
125a, and miR-99b) showed conserved regulation in both
Czimmerer et al. Genome Medicine  (2016) 8:63 Page 18 of 22
human and mouse alternatively activated macrophages
in vitro and in B. malayi nematode-infected mice in
vivo. We also showed that the alternative macrophage
activation-specific regulation of these miRNAs is IL-4Rα-
and STAT6-dependent. In addition, we determined that
both miR-342-3p and its host gene, EVL, are co-regulated
directly by STAT6 in mouse and human macrophages.
Finally, we demonstrated that macrophage survival
was reduced via miR-342-3p-dependent repression of
an anti-apoptotic gene network. These results are
consistent with the notion that IL-4/STAT6 signaling-
induced miR-342-3p is a potent negative feedback
regulator of macrophage cell number via induction of
apoptosis.
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